

# Psoriasis Case Consult 1

## Psoriasis With Scalp Involvement in a Patient With Skin of Color

### References

- Abrouk M, Lee K, Brodsky M, et al. Ethnicity affects the presenting severity of psoriasis. *J Am Acad Dermatol*. 2017;77(1):180-182.
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. *JAMA*. 2020;323(19):1945-1960.
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. *Ann Rheum Dis*. 2018;77(2):175-187.
- Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. *J Am Acad Dermatol*. 2024;90(4):775-782.
- Bronckers IMGJ, Maatkamp M, Kievit W, van de Kerkhof PCM, de Jong EMGJ, Seyger MMB. The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch Child-CAPTURE registry. *Br J Dermatol*. 2019;181(5):1099-1101.
- Choy EH. Clinical significance of Janus kinase inhibitor selectivity. *Rheumatology (Oxford)*. 2019;58(6):953-962.
- Dopytalska K, Sobolewski P, Błaszczak A, Szymańska E, Walecka I. Psoriasis in special localizations. *Reumatologia*. 2018;56(6):392-398.
- Gebauer K, Spelman L, Yamauchi PS, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. *J Am Acad Dermatol*. 2024; S0190-9622(24)00536-X.
- Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. *Expert Opin Pharmacother*. 2018;19(6):561-575.
- Leon A, Rosen JD, Hashimoto T, Fostini AC, Paus R, Yosipovitch G. Itching for an answer: A review of potential mechanisms of scalp itch in psoriasis. *Exp Dermatol*. 2019;28(12):1397-1404.
- Lytvyn Y, Sachdeva M, Mufti A, Yeung J. Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour. *Drugs Context*. 2022;11:2021-9-3.
- Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. *Clin Exp Dermatol*. 2016;41(5):486-489.
- Min X, Ungureanu D, Maxwell S, et al. Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2). *J Biol Chem*. 2015;290(45):27261-27270.
- Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. *Nat Rev Rheumatol*. 2024;20(4):232-240.
- Mosca M, Hong J, Haderl E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management. *Dermatol Ther (Heidelb)*. 2021;11(3):769-797.

- Nattkemper LA, Lipman ZM, Ingrassi G, et al. Neuroimmune mediators of pruritus in Hispanic scalp psoriatic itch. *Acta Derm Venereol.* 2023;103:adv4463.
  - Papadimitriou I, Bakirtzi K, Katoulis A, Ioannides D. Scalp psoriasis and biologic agents: A review. *Skin Appendage Disord.* 2021;7(6):439-448.
  - Pinter A, Tsianakas A, Eichner A; ScaTAC Study Group. Efficacy and safety of topical tacrolimus microemulsion applied twice daily in patients with mild to moderate scalp psoriasis. *Dermatol Ther (Heidelb).* 2024;14(2):521-532.
  - Sangha AM. Special considerations in the diagnosis and treatment of psoriasis. *J Clin Aesthet Dermatol.* 2021;14(12 Suppl 1):S24-S25.
  - Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol.* 2016;12(1):25-36.
  - Sonkoly E, Maul JT, Megna M, et al. Guselkumab in patients with scalp psoriasis: A post hoc analysis of the VOYAGE 2 phase III randomized clinical trial. *Acta Derm Venereol.* 2024;104:adv18672.
  - Strober B, Bachelez H, Crowley J, et al. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). *J Eur Acad Dermatol Venereol.* 2024;38(5):864-872.
  - Takeshita J, Eriksen WT, Raziano VT, et al. Racial differences in perceptions of psoriasis therapies: Implications for racial disparities in psoriasis treatment. *J Invest Dermatol.* 2019;139(8):1672-1679.e1.
  - Takeshita J, Augustin M, de Jong EMGJ, et al. Health-related QOL differs by race/ethnicity in North American patients with psoriasis: Results from PSOLAR. *J Invest Dermatol.* 2022;142(9):2528-2531.e3.
  - Yadav G, Yeung J, Miller-Monthrope Y, et al. Unmet need in people with psoriasis and skin of color in Canada and the United States. *Dermatol Ther (Heidelb).* 2022;12(11):2401-2413.
-